

## ASX ANNOUNCEMENT

15 January 2016

### RECCE Trade Mark Registered

Recce Ltd is pleased to announce that:

- (a) Following the Company's application, its Trade Mark RECCE has been accepted, and is thus registered in Australia.
- (b) Applications have been submitted additionally, for protection, in Europe, USA, Japan and China.
- (c) The applications include considerations of the foreign language aspects of the RECCE Trade Mark.

RECCE® antibiotics are protected by patents in the above countries, representing around 80% of the world pharmaceutical market.

For further information please visit [www.recce.com.au](http://www.recce.com.au) or contact:

#### Investor Relations

Peter Williams  
CFO & Company Secretary  
Recce Ltd  
Tel: +61 8 9253 9800

#### Media Communication

Karen Oswald – [karen.oswald@markocommunications.com.au](mailto:karen.oswald@markocommunications.com.au)  
Gary Buchholz – [gary@markocommunications.com.au](mailto:gary@markocommunications.com.au)  
Marko Communications  
Tel: +61 423 602 353

#### About Recce Ltd

Recce Ltd (ASX: RCE), led by Dr Graham Melrose, is a world-leader in synthetic-polymer antibiotics. RECCE® antibiotics have been synthesised by an extremely simple and economic method.

RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes and the development of a pilot plant for flow-system manufacture of RECCE® antibiotics - that should drive significant value for the Company.

